Meeting Banner
Abstract #4354

Quantitative DCE-MRI for differentiating high grade glioma recurrence from treatment-related changes:  Effect of T1 mapping method

Greg O. Cron1,2,3, Beckie Manouchehri4, Andrew Boivin3, Nader Zakhari1,3, Brandon Zanette5,6, Gerard H. Jansen1,2,3, John Woulfe1,2,3, Rebecca E. Thornhill1,2,3, Andreas Greiser7, Ian G. Cameron1,2,3,4, and Thanh B. Nguyen1,2,3

1The Ottawa Hospital, Ottawa, ON, Canada, 2Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4Carleton University, Ottawa, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada, 7Siemens Healthcare GmbH, Erlangen, Germany

After a patient has received treatment for a high grade glioma, a new enhancing lesion presents a common diagnostic dilemma: Malignant tumor recurrence and benign treatment-related changes (TRC) appear similar on conventional MRI. MRI tracer kinetic studies may help distinguish recurrence from TRC. We investigated whether Ktrans measurements using quantitative DCE-MRI can accurately diagnose recurrence. We also studied the effect of the DCE T1 mapping method (VFA versus LL). Ktrans values in recurrent tumor were higher than in TRC, providing sensitivity of 69-77%, specificity of 100%. The choice of T1 mapping had little effect on diagnostic accuracy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here